LOGO Exhibit 99.1 During the presentation, Atea will provide an update on the progress of its global Phase 3 program evaluating the potential best-in-class regimen of bemnifosbuvir (BEM) and ruzasvir (RZR) for the treatment of Hepatitis C virus (HCV). The Company will also detail challenges with current HCV therapeutics and the potential of Atea's regimen to meaningfully address them. In addition, the Company will discuss opportunities to expand HCV treatment through further adoption of the test-and-treat m ...

Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atea ...

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 7:30 a.m. PT in ...

Atea Pharmaceuticals ( AVIR ) is developing antiviral treatments for hepatitis C (HCV) and hepatitis E (HEV) viruses. Their lead candidate is bemnifosbuvir/ruzasvir ((BEM/RZR)) being developed for HCV cure, currently being evaluated in two parallel phase 3 trials, one in North America andhttps://biotechpharmainvestor.substack.comBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical b ...

Company Overview - Atea Pharmaceuticals (AVIR) is focused on developing antiviral treatments for hepatitis C (HCV) and hepatitis E (HEV) viruses [1] - The lead candidate for HCV treatment is bemnifosbuvir/ruzasvir (BEM/RZR), which is currently undergoing evaluation in two parallel phase 3 trials, one located in North America [1] Investment Insights - The investment style associated with Atea Pharmaceuticals includes a focus on clinical-stage biotech stocks, emphasizing both long-term ideas and event-driven trading [1] - The analyst's background in academia and medicine aids in evaluating the scientific fundamentals of biotech stocks, which is crucial for informed investment decisions [1]

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea o ...

Atea Pharmaceuticals (NasdaqGS:AVIR) FY Conference December 03, 2025 10:00 AM ET Company ParticipantsJohn Vavricka - Chief Commercial OfficerJean-Pierre Sommadossi - Founder, Chairman, and CEOArantxa Horga - Chief Medical OfficerOperatorAll right. Welcome, everybody, to Atea this morning. We've got JP, we've got the whole team, but we've got JP starting us off with a brief presentation on some recent announcements.Jean-Pierre SommadossiOkay, great. Thank you, John. Really appreciate the opportunity today. J ...

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 202 ...

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have ad-blockers enabled, indicating a need to disable them for proper access [1]

Core Insights - Atea Pharmaceuticals is hosting a virtual Key Opinion Leader (KOL) event focused on hepatitis C, featuring leading experts in hepatology and infectious diseases [2][3]. Company Overview - Atea Pharmaceuticals is led by Dr. Jean-Pierre Sommadossi, who serves as the Founder, Chairman, and CEO [2]. - The company aims to discuss the commercial market opportunity for hepatitis C virus (HCV) treatments during the event [3]. Expert Panel - The event includes a panel of experts from notable institutions, such as Dr. Jordan Feld from the University of Toronto, Dr. Eric Lawitz from the Texas Liver Institute, Dr. Anthony Martinez from the University of Buffalo, and Nancy Reau from Rush University Medical Center [3]. - Atea's Chief Commercial Officer, John Vavricka, along with other key executives, will present insights on the HCV market and treatment profiles [3].